news
Global bioreactor market to value over $16bn by 2027
A report indicates ongoing demand for COVID-19 vaccines and other biologics, as well as increasing investment will drive a 16.6 percent CAGR in the bioreactors market.
List view / Grid view
Biologics
news
Personalised cancer vaccine safe and potentially beneficial to patients
Mount Sinai researchers reveal that, in a Phase I trial, their personalised cancer vaccines targeting cancer neoantigens showed some early signs of potential benefit.
news
Novel time-temperature indicator could help preserve mRNA vaccines
Researchers have developed a novel sensor, known as a time-temperature indicator, that could be used to monitor the storage conditions of mRNA vaccines.
whitepaper
Brochure: Integrated bioprocessing
The journey from large molecule to approved biotherapeutic is long, costly, complex, and fraught with risk – yet rewards for success are substantial.
news
NIAID doses first patient with Moderna’s variant specific COVID-19 vaccine candidate
The trial will evaluate the safety and immunogenicity of the mRNA-1273.351 vaccine candidate in 200 healthy adult volunteers.
news
Celonic to produce 100 million doses of CureVac’s COVID-19 vaccine candidate
Production of CureVac’s CVnCoV vaccine will take place in Germany, with over 50 million doses expected to be produced in 2021.
whitepaper
Whitepaper: Advantages of single-layer film versus multilayer film
This paper takes a closer look at plastic storage bags for bioprocesses focusing on a shift from multilayer to single-layer storage solutions.
news
First ever Award for Extraordinary Impact on Health bestowed on Moderna and Pfizer
While announcing 2021’s Top 10 Clinical Research Achievement Awards, the US Clinical Research Forum revealed that Pfizer and Moderna would be honoured for their COVID-19 vaccines.
news
What strains should be in this year’s seasonal influenza vaccines?
The European Medicines Agency has published its recommendations for 2021-2022 seasonal influenza vaccine composition.
news
Lenzilumab™ significantly improves survival in hospitalised COVID-19 patients
In a Phase III trial, adding Lenzilumab™ to steroid and remdesivir regimens improved the likelihood of survival without need for mechanical ventilation by 54 percent.
news
African Union to receive 220 million doses of Janssen COVID-19 Vaccine
The African Vaccine Acquisition Trust (AVAT) has entered into an advanced purchase agreement for 220 million doses of Janssen COVID-19 Vaccine.
news
GSK to provide fill and finish capacity for Novavax’ COVID-19 vaccine
Under a new agreement, GlaxoSmithKline will provide the fill and finish manufacturing capacity for 60 million doses of Novavax’ COVID-19 vaccine for use in the UK.
whitepaper
Article: A holistic strategy to ensure CCI of sterile vials
A framework to enable a holistic approach to CCI that assures both primary packaging and process contribute to good CCI of sterile vial product.
news
WHO issues alert for falsified COVID-19 vaccine
The World Health Organization (WHO) has warned that a falsified COVID-19 vaccine, identified as Pfizer’s BNT162b2, could still be in circulation in the Americas.
news
FDA approves Abecma, the first cell-based gene therapy for adults with multiple myeloma
Abecma (idecabtagene vicleucel) was approved for adults with relapsed or refractory myeloma based on its 72 percent overall response rate in a trial.
